Provider Briefing: Zavzpret Access in 2026

Zavzpret (Zavegepant) has established itself as a valuable addition to the acute migraine armamentarium since its FDA approval in March 2023. As the only intranasal CGRP receptor antagonist, it fills a distinct clinical niche — particularly for patients who experience significant nausea during migraine attacks or who cannot tolerate oral medications.

However, your patients are likely reporting difficulty filling their Zavzpret prescriptions. This briefing covers what's happening with Zavzpret availability, the factors driving access challenges, and practical steps you can take to help your patients get this medication.

Current Shortage Status and Timeline

As of February 2026, Zavzpret is not listed on the FDA Drug Shortage Database. The supply chain from Pfizer remains intact, and the product is being manufactured and distributed normally.

What patients experience, however, is a functional access gap rather than a true shortage:

• March 2023: FDA approval of Zavzpret for acute migraine in adults
• 2023–2024: Initial rollout and formulary reviews; early reports of difficulty finding the medication at retail pharmacies
• 2025: Continued limited stocking at many retail chains; increasing use of specialty and mail-order pharmacy channels
• 2026 (current): Availability remains stable at the manufacturer level but inconsistent at the retail pharmacy level

This pattern is consistent with other high-cost, brand-name specialty medications where limited demand at individual pharmacy locations makes routine stocking economically unfavorable.

Prescribing Implications

When prescribing Zavzpret, consider the following access-related factors:

Prior Authorization and Step Therapy

Most commercial and Medicare Part D plans require prior authorization for Zavzpret. Many also mandate step therapy, typically requiring documented trial and failure of at least one triptan. Submitting prior authorization proactively — before the patient arrives at the pharmacy — can prevent significant delays.

Pharmacy Channel Considerations

Some payers route Zavzpret through specialty pharmacy networks rather than retail. When writing the prescription, clarify with the patient's plan whether retail fill is permitted or if the prescription should be directed to a specialty pharmacy. Sending a prescription to a retail pharmacy that cannot fill it wastes time for both the patient and your staff.

Patient Education at Point of Prescribing

Setting expectations during the prescribing visit reduces patient frustration. Consider advising patients that:

• Their local pharmacy may need to special-order Zavzpret (1-3 business days typical)
• Prior authorization may be required and can take several days
• Pfizer's savings programs can significantly reduce out-of-pocket costs
• Tools like Medfinder for Providers can help locate pharmacies with current stock

Current Availability Picture

The availability challenge is primarily a last-mile stocking issue, not a manufacturing or distribution shortage:

• Large chain pharmacies (CVS, Walgreens, Rite Aid): Inconsistent stocking; many locations will special-order but do not carry routinely
• Independent pharmacies: Variable; some that serve migraine patient populations stock it regularly
• Specialty pharmacies: Generally reliable availability with established fulfillment processes
• Mail-order pharmacies: Typically reliable once the patient is enrolled

Directing patients to check availability through Medfinder before visiting a pharmacy can significantly reduce the number of failed fill attempts.

Cost and Access Considerations

Zavzpret's cost profile is an important factor in prescribing decisions and patient adherence:

• Wholesale acquisition cost (WAC): Approximately $800–$1,100 per pack of 8 single-dose devices
• Typical commercial copay with savings card: As low as $0 per fill for eligible patients
• Typical commercial copay without savings card: $50–$250+ depending on formulary tier
• Cash price (uninsured): $800–$1,100

Pfizer Support Programs

• Zavzpret Savings Card: Available for commercially insured patients; can reduce copay to $0. Not valid for government insurance (Medicare, Medicaid, Tricare, VA).
• Pfizer RxPathways: Patient assistance program for uninsured or underinsured patients meeting income eligibility criteria; may provide Zavzpret at no cost.

For patients facing cost barriers, a comprehensive overview is available at Medfinder's Zavzpret savings guide. For provider-specific cost strategies, see our guide on helping patients save money on Zavzpret.

Tools and Resources for Your Practice

Medfinder for Providers offers real-time pharmacy inventory data that can be integrated into your prescribing workflow. Rather than sending patients out with a prescription and hoping their pharmacy has stock, you can check availability during the visit and direct the prescription accordingly.

Additional steps your practice can take:

1. Establish relationships with 1-2 pharmacies that reliably stock or quickly order Zavzpret, and direct patients to those locations.
2. Pre-submit prior authorizations when prescribing Zavzpret so the approval is in place before the patient attempts to fill.
3. Provide patients with savings program information at the point of prescribing — the Pfizer Savings Card application can be completed in-office.
4. Document step therapy failures thoroughly in the patient chart to support prior authorization appeals.

For a complete workflow guide, see how to help your patients find Zavzpret in stock.

Alternative Therapies to Consider

When Zavzpret is not accessible or appropriate, these alternatives may serve your patients:

• Ubrelvy (Ubrogepant): Oral CGRP antagonist; 50 mg or 100 mg tablet; similar mechanism but oral route
• Nurtec ODT (Rimegepant): Orally disintegrating CGRP antagonist; dual-approved for acute and preventive use
• Sumatriptan nasal spray: Generic available; significantly lower cost; contraindicated in cardiovascular disease
• Trudhesa (Dihydroergotamine): Nasal spray; ergot alkaloid; cardiovascular contraindications apply

The patient-facing alternatives guide provides detailed comparisons you can share with patients.

Looking Ahead

Several developments may impact Zavzpret access in the coming years:

• Formulary positioning: As real-world evidence accumulates and CGRP antagonists become more established, formulary placement may improve
• Pipeline developments: Oral Zavegepant is being studied for preventive migraine use, which could expand the patient population and potentially improve pharmacy stocking
• Generic timeline: No generic Zavegepant is expected in the near term; patent protection remains in effect

Final Thoughts

Zavzpret fills a genuine clinical need as the only intranasal CGRP receptor antagonist. The access challenges your patients face are real but manageable with proactive prescribing strategies, proper use of manufacturer support programs, and tools like Medfinder for Providers.

By anticipating access barriers at the point of prescribing — rather than leaving patients to navigate them alone — you can significantly improve the likelihood that your patients receive the treatment you've chosen for them.